Cargando…

Technical Evaluation of Commercial Mutation Analysis Platforms and Reference Materials for Liquid Biopsy Profiling

Molecular profiling from liquid biopsy, in particular cell-free DNA (cfDNA), represents an attractive alternative to tissue biopsies for the detection of actionable targets and tumor monitoring. In addition to PCR-based assays, Next Generation Sequencing (NGS)-based cfDNA assays are now commercially...

Descripción completa

Detalles Bibliográficos
Autores principales:	Weber, Sabrina, Spiegl, Benjamin, Perakis, Samantha O., Ulz, Christine M., Abuja, Peter M., Kashofer, Karl, van der Leest, Paul, Azpurua, Maria Aguirre, Tamminga, Menno, Brudzewsky, Dan, Rothwell, Dominic G., Mohan, Sumitra, Sartori, Alexander, Lampignano, Rita, Konigshofer, Yves, Sprenger-Haussels, Markus, Wikman, Harriet, Bergheim, Inger R., Kloten, Vera, Schuuring, Ed, Speicher, Michael R., Heitzer, Ellen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352370/ https://www.ncbi.nlm.nih.gov/pubmed/32560092 http://dx.doi.org/10.3390/cancers12061588

Ejemplares similares

Cell-free DNA analysis reveals POLR1D-mediated resistance to bevacizumab in colorectal cancer
por: Zhou, Qing, et al.
Publicado: (2020)

The potential of liquid biopsies for the early detection of cancer
por: Heitzer, Ellen, et al.
Publicado: (2017)

Circulating tumor cells and DNA as liquid biopsies
por: Heitzer, Ellen, et al.
Publicado: (2013)

Single circulating tumor cell sequencing for monitoring
por: Auer, Martina, et al.
Publicado: (2013)

Detection and Monitoring of Tumor-Derived Mutations in Circulating Tumor DNA Using the UltraSEEK Lung Panel on the MassARRAY System in Metastatic Non-Small Cell Lung Cancer Patients
por: van der Leest, Paul, et al.
Publicado: (2023)

Circulating Tumor Cell PD-L1 Expression as Biomarker for Therapeutic Efficacy of Immune Checkpoint Inhibition in NSCLC
por: Kloten, Vera, et al.
Publicado: (2019)

Multicenter Evaluation of Independent High-Throughput and RT-qPCR Technologies for the Development of Analytical Workflows for Circulating miRNA Analysis
por: Babayan, Anna, et al.
Publicado: (2020)

Changes in Colorectal Carcinoma Genomes under Anti-EGFR Therapy Identified by Whole-Genome Plasma DNA Sequencing
por: Mohan, Sumitra, et al.
Publicado: (2014)

Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide
por: Belic, Jelena, et al.
Publicado: (2018)

Preexisting TP53 mutation in therapy-related acute myeloid leukemia
por: Schulz, Eduard, et al.
Publicado: (2014)

Emerging concepts in liquid biopsies
por: Perakis, Samantha, et al.
Publicado: (2017)

Optimized Quantification of Fragmented, Free Circulating DNA in Human Blood Plasma Using a Calibrated Duplex Real-Time PCR
por: Horlitz, Martin, et al.
Publicado: (2009)

The potential of combined mutation sequencing of plasma circulating cell‐free DNA and matched white blood cells for treatment response prediction
por: van der Leest, Paul, et al.
Publicado: (2020)

Comparison of three commercial decision support platforms for matching of next-generation sequencing results with therapies in patients with cancer
por: Perakis, Samantha O, et al.
Publicado: (2020)

Multiplex genetic cancer testing identifies pathogenic mutations in TP53 and CDH1 in a patient with bilateral breast and endometrial adenocarcinoma
por: Heitzer, Ellen, et al.
Publicado: (2013)

Comparison of Circulating Cell-Free DNA Extraction Methods for Downstream Analysis in Cancer Patients
por: van der Leest, Paul, et al.
Publicado: (2020)

Immune microenvironment composition in non‐small cell lung cancer and its association with survival
por: Tamminga, Menno, et al.
Publicado: (2020)

Inference of transcription factor binding from cell-free DNA enables tumor subtype prediction and early detection
por: Ulz, Peter, et al.
Publicado: (2019)

Publisher Correction: Inference of transcription factor binding from cell-free DNA enables tumor subtype prediction and early detection
por: Ulz, Peter, et al.
Publicado: (2020)

Circulating tumor DNA as a biomarker for monitoring early treatment responses of patients with advanced lung adenocarcinoma receiving immune checkpoint inhibitors
por: van der Leest, Paul, et al.
Publicado: (2021)

The dynamic range of circulating tumor DNA in metastatic breast cancer
por: Heidary, Maryam, et al.
Publicado: (2014)

Pre‐analytical factors affecting the establishment of a single tube assay for multiparameter liquid biopsy detection in melanoma patients
por: Schneegans, Svenja, et al.
Publicado: (2020)

Residual Humidity in Paraffin-Embedded Tissue Reduces Nucleic Acid Stability
por: Abuja, Peter M., et al.
Publicado: (2023)

Whole-genome plasma sequencing reveals focal amplifications as a driving force in metastatic prostate cancer
por: Ulz, Peter, et al.
Publicado: (2016)

Germline variants in the SEMA4A gene predispose to familial colorectal cancer type X
por: Schulz, Eduard, et al.
Publicado: (2014)

Establishment of tumor-specific copy number alterations from plasma DNA of patients with cancer
por: Heitzer, Ellen, et al.
Publicado: (2013)

Circulating tumor cells in advanced non-small cell lung cancer patients are associated with worse tumor response to checkpoint inhibitors
por: Tamminga, Menno, et al.
Publicado: (2019)

History of Comparative Ophthalmics
por: Königshöfer,
Publicado: (1899)

GCparagon: evaluating and correcting GC biases in cell-free DNA at the fragment level
por: Spiegl, Benjamin, et al.
Publicado: (2023)

Liquid Biopsy Preservation Solutions for Standardized Pre-Analytical Workflows—Venous Whole Blood and Plasma
por: Grölz, Daniel, et al.
Publicado: (2018)

Microsieves for the detection of circulating tumor cells in leukapheresis product in non-small cell lung cancer patients
por: Tamminga, Menno, et al.
Publicado: (2020)

Profiling of circulating tumor DNA and tumor tissue for treatment selection in patients with advanced and refractory carcinoma: a prospective, two-stage phase II Individualized Cancer Treatment trial
por: Riedl, Jakob M., et al.
Publicado: (2021)

Multimodal Targeted Deep Sequencing of Circulating Tumor Cells and Matched Cell-Free DNA Provides a More Comprehensive Tool to Identify Therapeutic Targets in Metastatic Breast Cancer Patients
por: Keup, Corinna, et al.
Publicado: (2020)

Detection of AML-specific TP53 mutations in bone marrow–derived mesenchymal stromal cells cultured under hypoxia conditions
por: Müller, Marian, et al.
Publicado: (2019)

β‐catenin regulates FOXP2 transcriptional activity via multiple binding sites
por: Richter, Gesa, et al.
Publicado: (2020)

Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing
por: Heitzer, Ellen, et al.
Publicado: (2013)

On-treatment measurements of circulating tumor DNA during FOLFOX therapy in patients with colorectal cancer
por: Moser, Tina, et al.
Publicado: (2020)

Clinoptilolite in Dextran Sulphate Sodium-Induced Murine Colitis: Efficacy and Safety of a Microparticulate Preparation
por: Nizet, Stéphane, et al.
Publicado: (2018)

Cell-Free DNA Variant Sequencing Using CTC-Depleted Blood for Comprehensive Liquid Biopsy Testing in Metastatic Breast Cancer
por: Keup, Corinna, et al.
Publicado: (2019)

Long-lived cancer-resistant rodents as new model species for cancer research
por: Azpurua, Jorge, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_j8arur6sfkt91ennts7q3pmu8g